



## CLX Medical, Inc.

(OTC BB: CLXN)

29970 Technology Drive, Suite 203, Murrieta, CA 92563

Telephone: (951) 677-6735 / Facsimile: (951) 677-6573

investors@clxinvestments.com

www.clxinvestments.com

## May 2008 Newsletter

### CLX Medical, Inc. Announces Letter of Intent for Acquisition of Additional Medical Diagnostic Testing Product

#### New acquisition expected to have significant market potential

**C** LX Investment Company, Inc., which is focused on the launch and distribution of unique medical diagnostic testing products, has announced that after a period of initial due diligence and negotiations, the company has progressed to a letter of intent to acquire a rapid diagnostic device for the medical market.

The due diligence process will continue as CLX pursues a definitive agreement and the close of the acquisition of the device. Once the company has reached a mutually agreed upon point in its due diligence process, it will announce the name of the device and the market that it serves.

The acquisition target presents considerable synergies with the product line of Zonda, Incorporated, a majority owned subsidiary of CLX that has developed a rapid point of care test for chlamydia. CLX Investment Company is currently preparing to initiate clinical trials for the Zonda chlamydia test as part of the effort to achieve FDA clearance for the product. The company recently announced a validation study to perfect the testing protocol in preparation for the clinical trials.

As CLX supports the Zonda product line, it will continue to identify additional innovative products as potential acquisitions and opportunities for distribution relationships for CLX. CLX intends to acquire, license and distribute innovative medical diagnostic technologies that are ideally suited for further development, regulatory approval and distribution in the United States.

"The letter of intent is an important milestone in the process of acquiring this targeted product," commented Vera Leonard, chief executive officer of Zonda and CLX.

"We look forward to reaching the next steps in the process, including the announcement of the name of the product to be acquired, so we can begin discussing what we see as the significant market potential for this acquisition," Ms Leonard added.

In addition to the U.S. market, the new acquisition may have tremendous potential in Europe, where the Zonda chlamydia product is sold, and in other overseas markets.

#### Inside This Issue

**CLX Medical, Inc. Updates Process of Validation Study for Zonda's Rapid Point of Care Test for Chlamydia**

Page 2

**CLX Medical, Inc. Announces Increasing Interest and Sales of Zonda's Rapid Point of Care Test for Chlamydia**

Page 2

#### About the Company

**CLX Medical, Inc. is focused on the launch and distribution of unique medical diagnostic testing products. CLX holds a 51% equity interest in Zonda, Inc. and has targeted a new acquisition in the rapid diagnostic testing market. The Company also holds a common stock position, in ActionView International, Inc., a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.**

**For more information, please visit the CLX website at [www.clxinvestments.com](http://www.clxinvestments.com) and the Zonda website at [www.zondaincusa.com](http://www.zondaincusa.com).**

# CLX Medical, Inc. Updates Process of Validation Study for Zonda's Rapid Point of Care Test for Chlamydia

CLX Medical, Inc. announced that the first stages of a pre-clinical trials validation study on Zonda Incorporated's rapid point of care test for chlamydia have been initiated and that the testing itself is expected to commence once the required chlamydia cells have been grown and laboratory staff has been properly trained in the study procedures.

The validation study is designed to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product. With FDA clearance, CLX will seek to achieve widespread distribution for the HandiLab-C within the U.S., as well as broader distribution into worldwide markets.

IIT Research Institute (IITRI) has been engaged to serve as the laboratory that will conduct a validation study. IIT Research Institute has provided non-clinical research and development services to the U.S. government and to sponsors in the pharmaceutical, biotechnology, chemical, agrichemical, and personal products industries for more than 40 years.

IIT Research Institute operates more than 125,000 square feet of state-of-the-art laboratory and support space in its Chicago, Illinois facility. Additional information on IIT Research Institute can be found at [www.iitri.org](http://www.iitri.org).



"It is extremely important that a sound proof-of-concept and pre-clinical validation has been conducted prior to initiation of the clinical study, and we are pleased that the training and other preparations are currently underway," stated Vera Leonard, CEO of Zonda and CLX.

"The testing itself will occur in a relatively short period, but the work leading up to it is critically important, both for the study and for the clinical trials expected to be initiated afterwards.

"We look forward to receiving feedback from the validation study, which we expect to be completed by mid-June," Ms. Leonard added.

# Increasing Interest and Sales of Zonda's Rapid Point of Care Test for Chlamydia Reported in European Market

## Health Agencies Focus on the Growing Chlamydia Epidemic

Zonda Incorporated's European distributors have reported an increased interest in its diagnostic testing product for chlamydia, which has resulted in increased sales of the HandiLab-C test by those distributors.

Distributors in the United Kingdom, Belgium, the Netherlands and Luxemburg have reported the increase over recent months and attribute it to a greater focus on screening for chlamydia by national health organizations in those countries.



The National Chlamydia Screening Programme (NCSP) in the United Kingdom has put an increased focus on the chlamydia epidemic and encourages testing for all sexually active men and women under the age of 25.

The program in England was established in 2003 with the objective of controlling chlamydia through the early detection and treatment of asymptomatic infection. As in the United States chlamydia is now the most commonly reported sexually transmitted infection in the UK.



"Given the growing chlamydia epidemic, it is no surprise that interest in chlamydia screening products, including Zonda's HandiLab-C test for Chlamydia, is increasing in Europe as well as in the United States," commented Vera Leonard, CLX CEO.

"Chlamydia is a serious health problem, and we are currently positioning the Zonda chlamydia testing product to serve as an effective and readily available screening rapid point of care device for health care professionals worldwide," she added.

CLX has initiated the process of conducting clinical trials for Zonda's HandiLab-C test for Chlamydia as part of the process to achieve FDA clearance for the product.

### Forward-Looking Statements

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.